Relation Between COVID-19 Pts and Hyponatremia in Adreno Ortical Insufficient Patients.

• Sponsor: Assiut University (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05408481
• Collaborator: (none)
• Enrollment: 50
• Anticipated Duration (Months): 9

Study Details

Study Description

Brief Summary

Hyponatremia in COVID-19 patients with adrenal insufficiency

Condition or Disease	Intervention/Treatment	Phase
COVID-19	Diagnostic Test: Serum cortisol level

Detailed Description

Hyponatremia is the most prevalent hydroelectrolytic disorder in clinical practice, and is linked to higher rates of morbidity and mortality. 1, 2.Sodium balance disorder, particularly hyponatremia, is a common condition among hospitalized patients with COVID-19 . and it is associated with a higher risk of morbidity, mortality, and disability. Acute hyponatremia causes serious brain swelling that can lead to permanent disability or death. Chronic hyponatremia causes attention deficit, gait instability, and osteoporosis, Mechanisms of hyponatremia in coronavirus disease 2019 (COVID-19) patients. Osmotic syndrome of inappropriate antidiuretic hormone release (SIADH) as a major mechanism. Also hypovolemic hyponatremia that may have been common in COVID-19 patients since nausea, vomiting, diarrhea.we predict critical illness-related corticosteroid insufficiency (CIRCI) play a role in hyponatremia in COVID-19 , high percentage of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection in the study were treated with vasopressors (2). Angiotensin-converting enzyme 2 receptor and transmembrane serine protease 2 serine protease were colocalized in adrenocortical cells in the zona fasciculata and zona reticularis (2). plasma cortisol concentrations will be collected in critically ill patients with COVID-19 (2). The cortisol levels of critically ill patients with COVID-19 were low(2).We aimed to identify the previlence and mortality rate of hyponatremia in covid 19 patient with adrenal insufficiency . Our studies will present in Assiut hospital university on patients in isolation ward from October 2021 to October 2022.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 50 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Hyponatremia in COVID-19 Patients With Adrenal Insufficiency and Its Relation to Mortality and Survival Scores.
• Anticipated Study Start Date: Jun 1, 2022
• Anticipated Primary Completion Date: Dec 1, 2022
• Anticipated Study Completion Date: Mar 1, 2023

Outcome Measures

Primary Outcome Measures

1. The effect of hyponatremia on mortality of COVID-19 patient with adrenal insufficiency [Baseline]

   Na level will be measured in COVID-19 patients with adrenal insufficiency

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 80 Years
• Sexes Eligible for Study: All

Inclusion Criteria:

• 1-Suspected COVID-19 patients come to isolation hospital in Assuit. 2-Hyponatremia. 3- Adrenal insufficiency

Exclusion Criteria:

• Non-cooperative patients

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hossam Mostafa Abdel Raheem Gad El Rab, Dr, Assiut University
• ClinicalTrials.gov Identifier: NCT05408481
• Other Study ID Numbers: COVID-19 hyponatremia
• First Posted: Jun 7, 2022
• Last Update Posted: Jun 7, 2022
• Last Verified: Jun 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Hossam Mostafa Abdel Raheem Gad El Rab, Dr, Assiut University: Hyponatremia
• Additional relevant MeSH terms: COVID-19; Hyponatremia; Hydrocortisone

Study Results

No Results Posted as of Jun 7, 2022